Investigations of new lead structures for the design of novel cyclooxygenase-2 inhibitors.

On the basis of molecular modelling studies, five new compounds were synthesised and studied in an attempt to design new lead structures as selective COX-2 inhibitors.

[1]  A. Bennett,et al.  Activity of nimesulide on constitutive and inducible cyclooxygenases. , 1995, Arzneimittel-Forschung.

[2]  Andrew J. Dannenberg,et al.  Inhibition of Cyclooxygenase: A Novel Approach to Cancer Prevention , 1997, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[3]  G. Pasinetti,et al.  Cyclooxygenase and inflammation in Alzheimer's disease: Experimental approaches and clinical interventions , 1998, Journal of neuroscience research.

[4]  J. Gierse,et al.  Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. , 1995, The Biochemical journal.

[5]  K. Seibert,et al.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. Jou,et al.  Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents. , 1997, Journal of medicinal chemistry.

[7]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[8]  R. Egan,et al.  Prostaglandins, arachidonic acid, and inflammation. , 1980, Science.

[9]  M. Percival,et al.  The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. , 1999, Bioorganic & medicinal chemistry letters.

[10]  R. Kurumbail,et al.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1996, Nature.

[11]  S. Lebègue,et al.  A rapid density gradient technique for separating polymorphonuclear granulocytes , 1994, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[12]  R. S. Rogers,et al.  Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). , 1997, Journal of medicinal chemistry.

[13]  D. Lesieur,et al.  Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis. , 2001, Journal of medicinal chemistry.

[14]  A. Hsu,et al.  The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2* , 2000, The Journal of Biological Chemistry.

[15]  J. Falgueyret,et al.  Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. , 1994, Molecular pharmacology.

[16]  J. Salmon,et al.  Extraction and thin-layer chromatography of arachidonic acid metabolites. , 1982, Methods in enzymology.

[17]  J. Falgueyret,et al.  Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor , 1997, British journal of pharmacology.

[18]  Anne Ballinger,et al.  COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention , 2001, Expert opinion on pharmacotherapy.

[19]  R. Cramer,et al.  Validation of the general purpose tripos 5.2 force field , 1989 .

[20]  K. Seibert,et al.  The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. , 1990, The Journal of biological chemistry.

[21]  C. Koboldt,et al.  Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents. , 2000, Journal of medicinal chemistry.

[22]  D. Dewitt,et al.  Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. , 1993, The Journal of biological chemistry.

[23]  F. Breedveld,et al.  Efficacy of cyclooxygenase-2-specific inhibitors. , 2001, The American journal of medicine.

[24]  Thomas A. Halgren,et al.  Maximally diagonal force constants in dependent angle-bending coordinates. II. Implications for the design of empirical force fields , 1990 .

[25]  C. Hawkey,et al.  COX-2 inhibitors , 1999, The Lancet.

[26]  D. Lesieur,et al.  Condensation of 3‐methylbenzoxazolinone with α,β‐unsaturated acids , 1981 .

[27]  Klaus Lieb,et al.  Anti-inflammatory drugs: a hope for Alzheimer’s disease? , 2000, Expert opinion on investigational drugs.

[28]  M. Luyckx,et al.  Azithromycin Impact on Neutrophil Oxidative Metabolism Depends on Exposure Time , 1998, Inflammation.

[29]  L. Marnett,et al.  Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. , 2000, Journal of medicinal chemistry.

[30]  J. Famaey.  In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: An overview , 1997, Inflammation Research.